Spondyloarthritis & psoriatic arthritis
Prevalence and incidence of uveitis in patients with spondyloarthritis: the impact of the biologics era. Data from the international ASAS-COMOSPA study
Authors' conclusion
In our study, the risk of having suffered from at least one episode of uveitis ranged from 10% at the time of the diagnosis of axial SpA to 47% after 30 years of disease duration. Patients with disease onset after biologic therapy introduction showed a significantly lower prevalence and incidence of first episodes of uveitis.
Study context
- Population
- Patients fulfilling ASAS SpA classification criteria from 22 countries (ASAS-COMOSPA)
- Participants
- 3,984 patients
- Exposure
- SpA onset in biologics era vs non-biologics era
- Outcome
- Prevalence of uveitis (first episode)
Methodological detailsinternational, multicentre (22 countries), Cox regression, Log-Rank test
- International
- Multicentre (22 countries)
- Cox regression
- Log-Rank test
Main finding
As reported in the abstract
Prevalence at time of SpA diagnosis
10.5%
95% CI 9.5–11.4%
Prevalence after 30 years since SpA diagnosis
46.6%
41.6–51.5%
Observational data: associations, not effects.
Further findings
Prevalence of uveitis by era of SpA onset
P < 0.01
Incidence of uveitis by era of SpA onset
Factors associated with higher risk of uveitis
- HLA-B27 positivity, family history of uveitis, peripheral enthesitis and IBD associated with higher risk of uveitis
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →